References
- Ascott A, Mulick A, Yu AM, et al (2019) Atopic eczema and major cardiovascular outcomes: A systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol 143:1821–1829. https://doi.org/10.1016/j.jaci.2018.11.030.
- Schultz Larsen F (1993) Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 28:719–23. https://doi.org/10.1016/0190–9622(93)70099-f.
- Torres T, Ferreira EO, Gonçalo M, et al (2019) Update on Atopic Dermatitis. Acta Med Port 32:606–613. https://doi.org/10.20344/amp.11963.
- Spergel JM (2010) From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 105:99–106; quiz 107–9, 117. https://doi.org/10.1016/j.anai.2009.10.002.
- Bantz SK, Zhu Z, Zheng T (2014) The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma. J Clin Cell Immunol 5:. https://doi.org/10.4172/2155–9899.1000202.
- Avena-Woods C (2017) Overview of atopic dermatitis. Am J Manag Care 23:S115–S123.
- Langan SM, Irvine AD, Weidinger S (2020) Atopic dermatitis. Lancet 396:345–360. https://doi.org/10.1016/S0140–6736(20)31286–1.
- Lewis-Jones S (2006) Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract 60:984–92. https://doi.org/10.1111/j.1742–1241.2006.01047.x.
- Brown MM, Chamlin SL, Smidt AC (2013) Quality of life in pediatric dermatology. Dermatol Clin 31:211–21. https://doi.org/10.1016/j.det.2012.12.010.
- Ständer S (2021) Atopic Dermatitis. N Engl J Med 384:1136–1143. https://doi.org/10.1056/NEJMra2023911.
- Silverberg NB, Silverberg JI (2015) Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis? Cutis 96:359–61.
- Bieber T (2008) Atopic dermatitis. N Engl J Med 358:1483–94. https://doi.org/10.1056/NEJMra074081.
- Huang I-H, Chung W-H, Wu P-C, Chen C-B (2022) JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Front Immunol 13:1068260. https://doi.org/10.3389/fimmu.2022.1068260.
- Liu T, Li S, Ying S, et al (2020) The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front Immunol 11:594735. https://doi.org/10.3389/fimmu.2020.594735.
- Li H, Zhang Z, Zhang H, et al (2021) Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol 61:324–338. https://doi.org/10.1007/s12016–021–08880–3.
- Weidinger S, Illig T, Baurecht H, et al (2006) Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 118:214–9. https://doi.org/10.1016/j.jaci.2006.05.004.
- Li H, Zhang Z, Zhang H, et al (2021) Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol 61:324–338. https://doi.org/10.1007/s12016–021–08880–3.
- Totté JEE, van der Feltz WT, Hennekam M, et al (2016) Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 175:687–95. https://doi.org/10.1111/bjd.14566.
- Lunjani N, Hlela C, O’Mahony L (2019) Microbiome and skin biology. Curr Opin Allergy Clin Immunol 19:328–333. https://doi.org/10.1097/ACI.0000000000000542.
- Rudzki E, Samochocki Z, Rebandel P, et al (1994) Frequency and significance of the major and minor features of Hanifin and Rajka among patients with atopic dermatitis. Dermatology 189:41–6. https://doi.org/10.1159/000246781.
- Böhme M, Svensson A, Kull I, Wahlgren CF (2000) Hanifin’s and Rajka’s minor criteria for atopic dermatitis: which do 2-year-olds exhibit? J Am Acad Dermatol 43:785–92. https://doi.org/10.1067/mjd.2000.110070.
- Fishbein AB, Silverberg JI, Wilson EJ, Ong PY (2020) Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract 8:91–101. https://doi.org/10.1016/j.jaip.2019.06.044.
- Eichenfield LF, Tom WL, Chamlin SL, et al (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 70:338–51. https://doi.org/10.1016/j.jaad.2013.10.010.
- Silverberg JI, Guttman-Yassky E, Thaçi D, et al (2023) Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med 388:1080–1091. https://doi.org/10.1056/NEJMoa2206714.
- Wollenberg A, Barbarot S, Bieber T, et al (2018) Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. Journal of the European Academy of Dermatology and Venereology 32:657–682. https://doi.org/10.1111/jdv.14891.
- Schuler CF, Billi AC, Maverakis E, et al (2023) Novel insights into atopic dermatitis. J Allergy Clin Immunol 151:1145–1154. https://doi.org/10.1016/j.jaci.2022.10.023.
- Wollenberg A, Frank R, Kroth J, Ruzicka T (2009) Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 7:117–21. https://doi.org/10.1111/j.1610–0387.2008.06772.x.
- Sidbury R, Alikhan A, Bercovitch L, et al (2023) Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol 89:e1–e20. https://doi.org/10.1016/j.jaad.2022.12.029.
- Nakai K, Kubota Y, Soma G-I, Kohchi C (2019) The Effect of Lipopolysaccharide-containing Moisturizing Cream on Skin Care in Patients With Mild Atopic Dermatitis. In Vivo 33:109–114. https://doi.org/10.21873/invivo.11446.
- Wollenberg A, Werfel T, Ring J, et al (2023) Atopic Dermatitis in Children and Adults—Diagnosis and Treatment. Dtsch Arztebl Int 120:224–234. https://doi.org/10.3238/arztebl.m2023.0011.
- Wollenberg A, Kinberger M, Arents B, et al (2022) European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol 36:1904–1926. https://doi.org/10.1111/jdv.18429.
- Devillers ACA, Oranje AP (2006) Efficacy and safety of “wet-wrap” dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 154:579–85. https://doi.org/10.1111/j.1365–2133.2006.07157.x.
- Callen J, Chamlin S, Eichenfield LF, et al (2007) A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 156:203–21. https://doi.org/10.1111/j.1365–2133.2006.07538.x.
- El-Batawy MMY, Bosseila MA-W, Mashaly HM, Hafez VSGA (2009) Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 54:76–87. https://doi.org/10.1016/j.jdermsci.2009.02.002.
- Frankel HC, Qureshi AA (2012) Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 13:113–23. https://doi.org/10.2165/11597780–000000000–00000.
- Chovatiya R, Paller AS (2021) JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol 148:927–940. https://doi.org/10.1016/j.jaci.2021.08.009.
- Dogra S, Mahajan R, Indian Association of Dermatologists V and L (2015) Phototherapy for atopic dermatitis. Indian J Dermatol Venereol Leprol 81:10–5. https://doi.org/10.4103/0378–6323.148557.
- Musters AH, Mashayekhi S, Harvey J, et al (2021) Phototherapy for atopic eczema. Cochrane Database Syst Rev 10:CD013870. https://doi.org/10.1002/14651858.CD013870.pub2.
- Ortiz-Salvador JM, Pérez-Ferriols A (2017) Phototherapy in Atopic Dermatitis. Adv Exp Med Biol 996:279–286. https://doi.org/10.1007/978–3-319–56017–5_23.
- Silverberg NB (2017) Atopic dermatitis prevention and treatment. Cutis 100:173;177;192.
- Chu AWL, Wong MM, Rayner DG, et al (2023) Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 152:1470–1492. https://doi.org/10.1016/j.jaci.2023.08.029.
- Nowicki R, Trzeciak M, Wilkowska A, et al (2015) Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. Postepy Dermatol Alergol 32:239–49. https://doi.org/10.5114/pdia.2015.53319.
- Gürel Dİ, Soyer Ö, Şahiner ÜM (2023) Systemic treatments in atopic dermatitis in children. Turk J Pediatr 65:887–905. https://doi.org/10.24953/turkjped.2023.203.
- Liu HN, Wong CK (1997) In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Arch Dermatol Res 289:94–7. https://doi.org/10.1007/s004030050161.
- Drucker AM, Ellis AG, Bohdanowicz M, et al (2020) Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. JAMA Dermatol 156:659–667. https://doi.org/10.1001/jamadermatol.2020.0796.
- Dvorakova V, O’Regan GM, Irvine AD (2017) Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center. Pediatr Dermatol 34:528–534. https://doi.org/10.1111/pde.13209.
- El-Khalawany MA, Hassan H, Shaaban D, et al (2013) Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr 172:351–6. https://doi.org/10.1007/s00431–012–1893–3.
- Lyakhovitsky A, Barzilai A, Heyman R, et al (2010) Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol 24:43–9. https://doi.org/10.1111/j.1468–3083.2009.03351.x.
- Purvis D, Lee M, Agnew K, et al (2019) Long-term effect of methotrexate for childhood atopic dermatitis. J Paediatr Child Health 55:1487–1491. https://doi.org/10.1111/jpc.14478.
- Sidbury R, Davis DM, Cohen DE, et al (2014) Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 71:327–49. https://doi.org/10.1016/j.jaad.2014.03.030.
- Drucker AM, Eyerich K, de Bruin-Weller MS, et al (2018) Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 178:768–775. https://doi.org/10.1111/bjd.15928.
- Phan K, Smith SD (2020) Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat 31:810–814. https://doi.org/10.1080/09546634.2019.1642996.
- Murray ML, Cohen JB (2007) Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 32:23–7. https://doi.org/10.1111/j.1365–2230.2006.02290.x.
- Deleanu D, Nedelea I (2019) Biological therapies for atopic dermatitis: An update. Exp Ther Med 17:1061–1067. https://doi.org/10.3892/etm.2018.6989.
- Darsow U (2012) Allergen-specific immunotherapy for atopic eczema: updated. Curr Opin Allergy Clin Immunol 12:665–9. https://doi.org/10.1097/ACI.0b013e3283588cf4.
- Avena-Woods C (2017) Overview of atopic dermatitis. Am J Manag Care 23:S115–S123.
- Schuler CF, Billi AC, Maverakis E, et al (2023) Novel insights into atopic dermatitis. J Allergy Clin Immunol 151:1145–1154. https://doi.org/10.1016/j.jaci.2022.10.023.
- Sroka-Tomaszewska J, Trzeciak M (2021) Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci 22:. https://doi.org/10.3390/ijms22084130.
- Seegräber M, Srour J, Walter A, et al (2018) Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 11:467–474. https://doi.org/10.1080/17512433.2018.1449642.
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287–2303. https://doi.org/10.1016/S0140–6736(17)31191–1.
- Seegräber M, Srour J, Walter A, et al (2018) Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 11:467–474. https://doi.org/10.1080/17512433.2018.1449642.
- Wollenberg A, Blauvelt A, Guttman-Yassky E, et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437–449. https://doi.org/10.1111/bjd.19574.
- Blauvelt A, Thyssen JP, Guttman-Yassky E, et al (2023) Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 188:740–748. https://doi.org/10.1093/bjd/ljad022.
- Silverberg JI, Guttman-Yassky E, Thaçi D, et al (2023) Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med 388:1080–1091. https://doi.org/10.1056/NEJMoa2206714.
- Kabashima K, Matsumura T, Komazaki H, et al (2020) Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. N Engl J Med 383:141–150. https://doi.org/10.1056/NEJMoa1917006.
- Nakashima C, Yanagihara S, Otsuka A (2022) Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors. Allergol Int 71:40–46. https://doi.org/10.1016/j.alit.2021.10.004.
- Reich K, Thyssen JP, Blauvelt A, et al (2022) Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet 400:273–282. https://doi.org/10.1016/S0140–6736(22)01199–0.
- Simpson EL, Lacour J-P, Spelman L, et al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 183:242–255. https://doi.org/10.1111/bjd.18898.
- Silverberg JI, Simpson EL, Wollenberg A, et al (2021) Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. JAMA Dermatol 157:691–699. https://doi.org/10.1001/jamadermatol.2021.1273.